DJIA 16,461.32 -153.49 -0.92%
NASDAQ 4,382.85 -36.63 -0.83%
S&P 500 1,927.11 -14.17 -0.73%
market minute promo

12.71 -0.29 (-2.23%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

INFI $12.71 -2.23%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.05
Previous Close $13.00
Daily Range $12.65 - $13.25
52-Week Range $8.40 - $18.35
Market Cap $617.5M
P/E Ratio -4.26
Dividend (Yield) $0.00 (0.0%)
Volume 363,663
Average Daily Volume 608,458
Current FY EPS -$3.35

Sector

Healthcare

Industry

Drugs

Infinity Pharmaceuticals, Inc. (INFI) Description

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions. Website: http://www.infi.com/

News & Commentary Rss Feed

Dividend Aristocrats: Time to Buy AbbVie Inc Stock?

AbbVie is an innovative pharma company with an attractive yield and a strong outlook for top-line growth going forward. Here's why investors should dig into this top dividend stock.

Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Al

Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

AbbVie Does Not Stand To Lose Much If It Drops Shire Deal Now

3 Partnerships Pushing The Pharmaceutical Sector Forward

Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gile

Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options Driving M&A Valuation To $93, Gilead Most Likely Suitor

Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog

Infinity Pharmaceuticals (INFI) Soars: Stock Rises 7.1% - Tale of the Tape

AbbVie Is Betting Big On Infinity Pharmaceuticals But Should You?

Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog

See More INFI News...

INFI's Top Competitors

INFI $12.71 (-2.23%)
Current stock: INFI
AMGN $143.64 (-0.31%)
Current stock: AMGN
BIIB $309.07 (-5.42%)
Current stock: BIIB
CELG $94.76 (-0.22%)
Current stock: CELG